Mansi Paradkar
Ramanbhai Patel College of Pharmacy, India
Title: Formulation development of intranasal artemether microemulsion for the treatment of malaria
Biography
Biography: Mansi Paradkar
Abstract
Artemether (ARM) microemulsion (ME) for intranasal delivery was developed using Isopropyl Myristate (IPM) as oil, Cremophor EL as surfactant and propylene carbonate as co-surfactant by water titration method. The optimized batch ME1 was evaluated by globule size, zeta potential, viscosity, TEM and solubilization capacity. %In vitro Drug release using modified Franz diffusion cell and histopathological studies from ME1 was carried out through sheep nasal mucosa. Comparative in vivo anti-malarial performance of the developed ME1 was evaluated against the ARM solution and marketed oral ARM formulation (Larither®) Plasmodium berghei infected mice as per Peter’s four day protocol. The parameters studied were %parasitemia, activity against time and animal survival period. TEM micrographs indicated that ME1 had a nearly monodispersed spherical shape with size ranging about 30nm. The mean viscosity of about 106.7cP suggested increased residence time and -18.43±0.86 Zeta potential indicated stability. Significant improvement in drug solubility overcome dissolution rate-limited absorption of ARM and this was realized with higher permeation coefficient during ex-vivo drug release studies. Histological examination of formulations did not show any remarkable damage to nasal mucosa. The animals treated with ME1 exhibited highest reduction in the percent parasitemia and 4 fold higher antimalarial activity with reduced mortality rate as compared to all other groups (P < 0.05). This demonstrates the utility of the microemulsion approach in improving the delivery and therapeutic efficacy of ARM through intranasal administration for the treatment of malaria.